Stock XENE XENON PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Real-time Estimate Cboe BZX
Other stock markets
 02:14:41 2024-04-29 pm EDT 		5-day change 1st Jan Change
42.54 USD +5.02% Intraday chart for Xenon Pharmaceuticals Inc. +6.75% -7.27%
Apr. 19 Xenon Pharmaceuticals Inc. Announces Board Resignations CI
Mar. 11 Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xenon Pharmaceuticals Inc. Announces Board Resignations
CI
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
GL
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GL
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
GL
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
GL
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
AQ
Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing
MT
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing
MT
Xenon Pharmaceuticals : Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission - Form 8-K
PU
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
GL
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
AQ
Needham Adjusts Price Target on Xenon Pharmaceuticals to $62 From $50, Maintains Buy Rating
MT
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk
MT
Wedbush Raises Xenon Pharmaceuticals' PT to $51 From $46, Continues to See XEN1101 as Differentiated Asset; Maintains Outperform Rating
MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Xenon Pharmaceuticals Q4 Net Loss Widens
MT
Transcript : Xenon Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 29, 2024
Xenon Pharmaceuticals: Q4 Earnings Snapshot
AQ
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XENE Stock
  4. News Xenon Pharmaceuticals Inc.